Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
28.05. | Leerink cuts Boundless Bio stock rating on program setback | 2 | Investing.com | ||
27.05. | Boundless Bio lays off 33% of staff as lead program stumbles | 2 | FierceBiotech | ||
23.05. | Boundless Bio To Reduce Its Workforce By About One-third | - | RTTNews | ||
BOUNDLESS BIO Aktie jetzt für 0€ handeln | |||||
23.05. | Boundless Bio, Inc.: Boundless Bio Announces Portfolio Prioritization and Runway Extension | 135 | GlobeNewswire (Europe) | Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first... ► Artikel lesen | |
23.05. | Boundless Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
09.05. | Boundless Bio GAAP EPS of $0.71 beats by $1.44 | 1 | Seeking Alpha | ||
09.05. | Boundless Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
09.05. | Boundless Bio, Inc.: Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights | 91 | GlobeNewswire (Europe) | Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 Novel Kinesin program on track... ► Artikel lesen | |
09.05. | Boundless Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
27.03. | Boundless Bio, Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
27.03. | Boundless Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
03.02. | Boundless Bio Appoints Robert Doebele As Chief Medical Officer | - | RTTNews | ||
03.02. | Boundless Bio, Inc.: Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer | 160 | GlobeNewswire (Europe) | SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies... ► Artikel lesen | |
13.12.24 | Boundless Bio drops clinical-stage cancer drug over phase 1 data, shakes up C-suite | 7 | FierceBiotech | ||
12.12.24 | Boundless Bio, Inc.: Boundless Bio Announces Pipeline and Leadership Updates | 176 | GlobeNewswire (Europe) | Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial Third ecDTx program advancing, with plans for development candidate nomination by mid-2025 Operating runway extended... ► Artikel lesen | |
12.12.24 | Boundless Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
14.10.24 | Boundless Bio, Inc.: Boundless Bio Announces Departure of Chief Financial Officer | 239 | GlobeNewswire (Europe) | SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies... ► Artikel lesen | |
12.08.24 | Boundless Bio, Inc.: Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results | 128 | GlobeNewswire (Europe) | BBI-355 POTENTIATE clinical trial ongoing with initiatives implemented to expedite enrollment in combination cohorts; initial proof-of-concept data now expected in the second half of 2025 BBI-825... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 99,25 | +1,79 % | BioNTech: Milliardendeal mit Bristol Myers Squibb - Aktie schießt ins Plus | BioNTechs Aktien schießen in der US-Vorbörse am Montag regelrecht nach oben: Aktuell werden 106,10 Dollar notiert nach einem NASDAQ-Schlusskurs bei 95,81 Dollar vom Freitag. Der Grund für den Kursanstieg... ► Artikel lesen | |
EVOTEC | 7,170 | +0,36 % | Evotec, GFT Technologies, InflaRx, Nordex, Rheinmetall, ThyssenKrupp - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
CUREVAC | 3,980 | +2,00 % | CureVac mit SPEZIAL-MELDUNG: Insider kaufen massenhaft Anteile - Das dürfen Sie nicht verpassen! | ||
AMGEN | 252,35 | +0,34 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
NOVAVAX | 6,251 | -0,16 % | Schock-News für Novavax Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
BIOGEN | 115,80 | +0,17 % | DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck | ||
VIVOSIM LABS | 1,570 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 1,910 | 0,00 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
MAINZ BIOMED | 2,775 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed gibt Interim-Ergebnisse seiner klinischen Studie eAArly DETECT 2 bekannt | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed gibt Interim-Ergebnisse seiner klinischen Studie eAArly DETECT 2 bekannt
16.05.2025 /... ► Artikel lesen | |
VIKING THERAPEUTICS | 23,800 | +0,63 % | Could Viking Therapeutics Become the Next Eli Lilly? | ||
INTELLIA THERAPEUTICS | 6,774 | +0,83 % | Canaccord Genuity lowers Intellia stock price target to $54 | ||
BIOCRYST PHARMACEUTICALS | 9,610 | -0,52 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
TEMPUS AI | 54,68 | -0,62 % | XFRA NEW INSTRUMENTS AVAILABLE ON 03.06.2025 | The following instruments on XETRA do have their first trading 03.06.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 03.06.2025
Aktien
1 US88023B1035 Tempus AI Inc.
2 KYG9482E1180... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 34,950 | +0,81 % | FDA Grants Platform Technology Status To Sarepta's RAAVrh74 Vector | WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT), Wednesday announced that the FDA has designated its rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 for limb-girdle... ► Artikel lesen | |
CARDIOL THERAPEUTICS | 1,300 | +2,52 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders | Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory... ► Artikel lesen |